Meeting
2013 Genitourinary Cancers Symposium
HER2 expression in patients (pts) with surgically resected urothelial cancer at high risk of recurrence screened for the phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy targeting HER2.
Authors
Michael F. Press
University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA
Michael F. Press , Peter H. O'Donnell , Elizabeth R. Plimack , Leonard G. Gomella , David I. Quinn , Padmanee Sharma , Todd DeVries , Robert Brownell Sims , Melissa Chen , Dean F. Bajorin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Prostate, Penile, Urethral, and Testicular Cancer, and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancer
Sub Track
Urothelial Carcinoma
Clinical Trial Registration Number
NCT01353222
Citation
J Clin Oncol 31, 2013 (suppl 6; abstr 292)
DOI
10.1200/jco.2013.31.6_suppl.292
Abstract #
292
Poster Bd #
H3
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Preliminary HER2 expression data from NeuACT, the phase II randomized, open-label trial of DN24-02 in patients (pts) with surgically resected HER2+ urothelial cancer (UC) at high risk for recurrence.
First Author: Michael F. Press
Poster
2014 ASCO Annual Meeting
Preliminary product parameter and safety results from NeuACT, a phase 2 randomized, open-label trial of DN24-02 in patients with surgically resected HER2+ urothelial cancer at high risk for recurrence.
First Author: Dean F. Bajorin
Poster
2013 ASCO Annual Meeting
Preliminary safety, product parameters, and immune response assessments from a phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy (ACI), in patients (pts) with surgically resected HER2+ urothelial cancer (UC) at high risk for recurrence.
First Author: Dean F. Bajorin
Poster
2011 ASCO Annual Meeting
Design of a phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy targeting HER2/neu, in patients with surgically resected urothelial cancer at high risk of recurrence.
First Author: D. F. Bajorin